Molecular Complexities and Biomarkers in
Gastrointestinal Cancers: Addressing Unmet Needs in the Evolving
Paradigm of Immunotherapies
A continuing medical education activity sponsored by NAMCP and AAMCN.
The Promise of Immunotherapy in the
Management of Gastrointestinal Cancers: What Does Managed Care Need
to Know About Checkpoint Inhibition and Biomarkers in Colorectal and
Gastric Tumors is a 3-part live webinar series that will provide
attendees with the latest information in the management of GI
This is Part 1 of the series focusing on molecular complexities and
biomarkers in GI cancer
This activity is an archive from the webinar held March 13, 2019
This activity is valid from April 1, 2019 to Apriil 1, 2020
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
To print or save your certificate, you will need to click on the
“download” button and either print or save.
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by an educational grant from
Merck Sharp & Dohme Corp.
Immunotherapy has now become a key component of the treatment
arsenal for colorectal and gastric or gastroesophageal junction
cancers, and extensive investigations are underway to further refine
and expand its role across the spectrum of gastrointestinal (GI)
cancers. Identifying the patients most likely to benefit from
immune-based therapies is essential for maximizing the potential of
checkpoint inhibitors in the management of these tumors, and
predictive biomarkers can be useful in this regard. What’s the
latest from clinical trials assessing immunotherapies in different
GI cancers? When and how should MSI/MMR status and PD-L1 expression
testing be performed to guide clinical decisions? What does managed
care need to know? These and other key topics are explored by top
experts in this webinar series.
This webinar is part 1 of a 3-part live
webinar series on immunotherapies in GI Cancers. This webinar will
focus on molecular complexities and biomarkers in GI cancer and how
they help shape treatment.
Upon completion of this
activity, participants will be able to:
Discuss the mechanisms of action of
immune checkpoint inhibitors and the rationale for checkpoint
inhibition in the treatment of Gastrointestinal (GI) cancers
Examine the current guideline
recommendations for MSI-H/dMMR testing, as well as implications
for treatment selection for patients with metastatic MSI-H/dMMR
Analyze how current biomarkers for
immunotherapy, including MSI-H/dMMR, PD-L1, TMB, and others
across the spectrum of GI cancers, may inform treatment choices
Explore strategies for the
prevention & optimal management of immune-related adverse
effects in GI cancers
||Tanios Bekaii-Saab, MD,
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer, Mayo Clinic
Vice-Chair and Section Lead, Division of Medical
Senior Associate Consultant, Mayo Clinic AZ
is a consultant for AbbVie, Armo, Silajen, and
Immuneering. He is on an advisory board/panel for
Imugene. He has received financial or material support
MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships
Will Williams has no relevant financial relationships to
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is
accredited by the Accreditation Council for Continuing Medical
Education (ACCME) to provide continuing medical education for
NAMCP designates this enduring material for a maximum of 1 AMA PRA
Category I creditsTM.
The American Association of Managed Care Nurses (AAMCN) is
accredited as a provider of continuing nursing education by the
American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hour toward CMCN recertification
This presentation is supported by
an educational grant from
Merck Sharp & Dohme Corp.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue